Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the completion of its previously announced underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock (collectively, the “warrants”).
Each share of common stock was sold together with one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock, at a combined price to the public of $1.00 per share of common stock and accompanying warrants, for gross proceeds of $15.0 million and net proceeds of approximately $13.6 million after deducting underwriting discounts and commissions and estimated offering expenses payable by Achaogen. All of the securities are being offered by Achaogen.
H.C. Wainwright & Co. acted as the sole book-running manager for the offering.
Achaogen currently expects to use the net proceeds from this offering to fund commercialization of ZEMDRI® in the United States, the regulatory approval process for plazomicin in Europe and the development of its product candidate C-Scape, and any remaining proceeds for working capital and general corporate purposes, including its review of strategic alternatives and search for additional non-dilutive funding opportunities.
A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission (SEC). This offering was made solely by means of such registration statement, including a prospectus supplement and accompanying prospectus relating to and describing the terms of the offering and forming a part of the registration statement, which has been filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained by visiting the SEC's website at www.sec.gov or from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or by emailing email@example.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Achaogen is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen's first commercial product is ZEMDRI, for the treatment of adults with complicated urinary tract infections, including pyelonephritis. The Achaogen ZEMDRI program was funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). The Company is currently developing C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, which is also supported by BARDA. C-Scape is investigational, has not been determined to be safe or efficacious, and has not been approved for commercialization.
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Achaogen's statements regarding the use of proceeds of the public offering. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Achaogen's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; the risks and uncertainties of product sales and effectiveness; the risk of when bacteria will evolve resistance to ZEMDRI; Achaogen's reliance on third-party contract manufacturing organizations for manufacture and supply, including sources of certain raw materials; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Achaogen's patents or proprietary rights; and the risk that Achaogen's proprietary rights may be insufficient to protect its technologies and product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Achaogen business in general, see Achaogen's prospectus supplement filed with the SEC on February 19, 2019, including the documents incorporated by reference therein, which includes Achaogen's current and future reports filed with the SEC, including its Annual Report on Form 10-K filed on February 27, 2018, and its Quarterly Report on Form 10-Q filed on November 8, 2018. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor and Media Contact: